The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E.
Ordóñez JL, et al. Among authors: carcaboso am.
Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303.
Oncotarget. 2015.
PMID: 26056084
Free PMC article.